These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

323 related articles for article (PubMed ID: 23542173)

  • 41. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
    [TBL] [Abstract][Full Text] [Related]  

  • 42. HER1/EGFR targeting: refining the strategy.
    Pérez-Soler R
    Oncologist; 2004; 9(1):58-67. PubMed ID: 14755015
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cross-talk between the ErbB/HER family and the type I insulin-like growth factor receptor signaling pathway in breast cancer.
    Jin Q; Esteva FJ
    J Mammary Gland Biol Neoplasia; 2008 Dec; 13(4):485-98. PubMed ID: 19034632
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
    Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
    Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Prediction of signaling cross-talks contributing to acquired drug resistance in breast cancer cells by Bayesian statistical modeling.
    Azad AK; Lawen A; Keith JM
    BMC Syst Biol; 2015 Jan; 9():2. PubMed ID: 25599599
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Novel targeted therapies to overcome trastuzumab resistance in HER2-overexpressing metastatic breast cancer.
    Huang Y; Fu P; Fan W
    Curr Drug Targets; 2013 Jul; 14(8):889-98. PubMed ID: 23531110
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting HER1/EGFR: a molecular approach to cancer therapy.
    Arteaga C
    Semin Oncol; 2003 Jun; 30(3 Suppl 7):3-14. PubMed ID: 12840796
    [TBL] [Abstract][Full Text] [Related]  

  • 48. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
    Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR
    Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Epidermal growth factor receptor dependence in human tumors: more than just expression?
    Arteaga CL
    Oncologist; 2002; 7 Suppl 4():31-9. PubMed ID: 12202786
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members.
    Wheeler DL; Huang S; Kruser TJ; Nechrebecki MM; Armstrong EA; Benavente S; Gondi V; Hsu KT; Harari PM
    Oncogene; 2008 Jun; 27(28):3944-56. PubMed ID: 18297114
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pharmacological background of EGFR targeting.
    Castillo L; Etienne-Grimaldi MC; Fischel JL; Formento P; Magné N; Milano G
    Ann Oncol; 2004 Jul; 15(7):1007-12. PubMed ID: 15205192
    [TBL] [Abstract][Full Text] [Related]  

  • 52. HER family in cancer progression: From discovery to 2020 and beyond.
    Kumar R; George B; Campbell MR; Verma N; Paul AM; Melo-Alvim C; Ribeiro L; Pillai MR; da Costa LM; Moasser MM
    Adv Cancer Res; 2020; 147():109-160. PubMed ID: 32593399
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.
    Kurokawa H; Arteaga CL
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4436s-4442s; discussion 4411s-4412s. PubMed ID: 11916237
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
    Rusnak DW; Lackey K; Affleck K; Wood ER; Alligood KJ; Rhodes N; Keith BR; Murray DM; Knight WB; Mullin RJ; Gilmer TM
    Mol Cancer Ther; 2001 Dec; 1(2):85-94. PubMed ID: 12467226
    [TBL] [Abstract][Full Text] [Related]  

  • 55. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.
    Li D; Ambrogio L; Shimamura T; Kubo S; Takahashi M; Chirieac LR; Padera RF; Shapiro GI; Baum A; Himmelsbach F; Rettig WJ; Meyerson M; Solca F; Greulich H; Wong KK
    Oncogene; 2008 Aug; 27(34):4702-11. PubMed ID: 18408761
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis.
    Larsen AK; Ouaret D; El Ouadrani K; Petitprez A
    Pharmacol Ther; 2011 Jul; 131(1):80-90. PubMed ID: 21439312
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dual EGFR/HER2 inhibition sensitizes prostate cancer cells to androgen withdrawal by suppressing ErbB3.
    Chen L; Mooso BA; Jathal MK; Madhav A; Johnson SD; van Spyk E; Mikhailova M; Zierenberg-Ripoll A; Xue L; Vinall RL; deVere White RW; Ghosh PM
    Clin Cancer Res; 2011 Oct; 17(19):6218-28. PubMed ID: 21844010
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR.
    Zhang YW; Staal B; Essenburg C; Lewis S; Kaufman D; Vande Woude GF
    Mol Cancer Ther; 2013 Aug; 12(8):1429-41. PubMed ID: 23720767
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
    Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
    Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors.
    Karamouzis MV; Konstantinopoulos PA; Papavassiliou AG
    Lancet Oncol; 2009 Jul; 10(7):709-17. PubMed ID: 19573800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.